Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CBD Life Sciences (OTCPK:CBDL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CBD Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was $1.35 Mil.
CBD Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBD Life Sciences EV-to-EBIT Related Terms
CBD Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CBD Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CBD Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CBD Life Sciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CBD Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CBD Life Sciences's EV-to-EBIT falls into.
CBD Life Sciences's current Enterprise Value is $1.19 Mil.
CBD Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CBD Life Sciences (CBDL) has a EV-to-EBIT of 31.56 as of Sep. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CBD Life Sciences and its competitors.
Is CBD Life Sciences' EV-to-EBIT too high?
CBD Life Sciences' current EV-to-EBIT is 31.56. The Drug Manufacturers industry median EV-to-EBIT is 16.03. CBD Life Sciences' value of 31.56 is 96.9% above this industry median.
How does CBD Life Sciences' EV-to-EBIT compare to QPAG and ADGO?
CBD Life Sciences' EV-to-EBIT of 31.56 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 16.03. CBD Life Sciences' value of 31.56 is 96.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.03, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CBD Life Sciences's current EV-to-EBIT of 31.56 is 96.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CBD Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CBD Life Sciences's current EV-to-EBIT is 31.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CBD Life Sciences stock overvalued right now?
CBD Life Sciences (CBDL) has a current EV-to-EBIT of 31.56. The current EV-to-EBIT is 31.56 and 96.9% above the Drug Manufacturers industry median of 16.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CBD Life Sciences (CBDL), the current EV-to-EBIT is 31.56 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CBD Life Sciences Inc is developing and marketing a line of cannabidiol-based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBDL has been successfully added to your 
